New Publications on Infantile Hemangioma released this month:
J Eur Acad Dermatol Venereol. 2010 Jun;24(6):631-8.
Infantile haemangiomas: a challenge in paediatric dermatology.
Schwartz RA, Sidor MI, Musumeci ML, Lin RL, Micali G.
New Jersey Medical School, Newark, NJ, USA. email@example.com
Infantile haemangiomas, common benign vascular tumours of childhood, are characterized by rapid growth during the first year of life and a slow regression that is usually completed at 7-10 years of age. These tumours are composed of endothelial cells with high mitotic rates and stromal components such as fibroblasts, mast cells and pericytes. Haemangiomas become a challenge when they are part of a syndrome, are located in certain areas of the body or when complications develop. The above-mentioned factors also influence the treatment modality used. However, although there remain many uncertainties regarding management, the beta-adrenergic receptor blocker propranolol is a promising new candidate for first-line systemic therapy. It produces such a dramatic and rapid response that the appearance of an infantile haemangioma should impart expeditious consideration of the risks and benefits of its use.
PMID: 20565561 [PubMed - in process]
Int J Pediatr Otorhinolaryngol. 2010 Jun 15. [Epub ahead of print]
Management of infantile subglottic hemangioma: Acebutolol or propranolol?
Blanchet C, Nicollas R, Bigorre M, Amedro P, Mondain M.
ENT Department, CHU Montpellier, France.
The successful management of subglottic hemangioma with propranolol has been reported. We report three cases of subglottic hemangioma treated with the cardioselective beta-blocker acebutolol, 8mg/kg/day. Treatment was efficient in two cases while an open procedure was necessary in the third child. In our experience, acebutolol could be easily administered in oral form twice-a-day only with a dose that was adaptable according to the growth of the child and showed no side effects. We also report a case of rebound growth after beta-mimetic drug use and the efficiency of propranolol treatment in such a recurrence. Considering the lack of side effects and the advantages in terms of administration, we suggest acebutolol as a first-line treatment of subglottic hemangiomas for which intervention is required. Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
PMID: 20557953 [PubMed - as supplied by publisher]
J. Dermatol. 2010 Apr;37(4):283-98.
Recent progress in studies of infantile hemangioma.
Jinnin M, Ishihara T, Boye E, Olsen BR.
Department of Dermatology and Plastic Surgery, Graduate School of Medical and Pharmaceutical Sciences, Kumamoto University, Honjo, Kumamoto, Japan. firstname.lastname@example.org
A hallmark of infantile hemangioma, the most common tumor of infancy, is its dramatic growth after birth, by diffuse proliferation of immature endothelial cells, followed by spontaneous regression. The growth and involution of infantile hemangioma is quite different from other vascular anomalies, which do not regress and can occur at any time during life. Some hemangioma lesions can be extremely disfiguring and destructive to normal tissue and may even be life-threatening. Unfortunately, existing therapeutic approaches have limited success and significant adverse effects of some treatment modalities limit their use. Better understanding of the pathogenesis of hemangioma will enable the development of better therapeutic strategies. Here, we review recent studies and new hypotheses on the pathogenesis of the tumor. Detailed mechanisms of activated vascular endothelial growth factor signaling in tumor cells, identification of their origin and characterization of multipotent stem cells that can give rise to infantile hemangioma are shedding new light on this intriguing vascular tumor.
PMID: 20507397 [PubMed - in process]